MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Cerus Corporation Cash Conversion Cycle 2011-2026 | CERS
Annual Cash Conversion Cycle Cerus Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47 | 59.2 | 68.3 | 57.7 | 53 | 60.8 | 36.3 | -16.3 | 145 | 135 | 149 | 142 | 176 | 97.2 | 102 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 176 | -16.3 | 87.4 |
Quarterly Cash Conversion Cycle Cerus Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.33 | 6.28 | 3.24 | - | -7.99 | -9.02 | -20 | - | -32.4 | -30.3 | -41.9 | - | -4.8 | -7.97 | -9.79 | - | 164 | 192 | - | - | - | - | - | - | 91.8 | - | - | - | 81.4 | - | - | - | - | - | - | - | 49.1 | 44 | 54.8 | - | 60.1 | 82.4 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 192 | -41.9 | 32.1 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 330.34 | 3.6 % | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Evogene Ltd.
EVGN
|
-32.5 | $ 0.79 | 1.22 % | $ 27.9 M |  Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - | Russia |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.89 | -4.33 % | $ 4.85 M | China |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
120 | - | -13.85 % | $ 16.1 M | USA |
 |
AbbVie
ABBV
|
284 | $ 206.69 | -1.01 % | $ 366 B | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Viela Bio, Inc.
VIE
|
139 | - | - | $ 2.91 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.39 | -3.69 % | $ 1.01 B | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Ardelyx
ARDX
|
885 | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.23 | -0.12 % | $ 6.83 B |  Spain |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.32 | -4.35 % | $ 339 M | USA |